Materials Literature
按标题、摘要、年份、主题和来源检索公开元数据。结果保留作者、摘要、分类与原始来源链接。
Abstract Background: Glioblastoma Multiforme (GBM), an aggressive brain cancer, is known for its treatment resistant recurrence and lethality. The diffuse migration and invasion of GBM cells commonly occurs along brain white matter tracts in linear confined spaces between axons and has significant clinical implication…
Abstract Glioblastoma multiforme (GBM) is a lethal brain tumor currently without successful treatment options. Chemotherapeutic agents are the frontline in the management of GBM. Nonetheless, accessibility of the brain tumor is greatly impeded by the poor blood-brain barrier (BBB) penetration of drugs, which needs imm…
Abstract Introduction: Ovarian cancer recurrence and survival rates have remained stagnant over time with current therapeutics displaying low efficacy and often rendered ineffective by degradation. This work presents novel fusogenic peptides that will electrostatically complex with siRNAs and cause a pH-responsive ins…
Abstract Background: Carfilzomib (CFZ), a proteasome inhibitor used to treat multiple myeloma (MM), has been associated with risk for cardiotoxicity including heart failure (HF). There is a lack of data on the mechanism underlying CFZ-induced cardiotoxicity. Our study aims to better understand molecular mechanisms of…
Abstract Lung cancer accounts for most number of cancer related death, reporting over 26.5% of all cancer deaths in United States alone. Among the risk factors, along with smoking, occupational as well as environmental exposure of carcinogens is considered as major driver of lung cancer in most cases. In that context,…
Abstract Eliciting effective tumor antigen-specific immunity requires targeting the initial stages of the anticancer immunity cycle, including activation of antigen presenting cells (APCs) for tumor antigen uptake and presentation, and T cell priming. Here, the research aimed to explore the novel immunotherapeutic str…
Abstract With systemic chemotherapy, only 1-2% of the administered dose reaches a localized tumor, while the remaining leads to adverse off-target toxicities, including immunosuppression. Hence, there is a critical need to locally deliver cytotoxics directly to the tumor. Our patented approach (SQ3370) consists of: 1.…
Abstract BACKGROUND Glioblastoma (GBM) is the most lethal primary brain cancer (median survival: 15-17 months, 5-year survival: 5.6%). Standard interventions consist of aggressive surgical resection, radiotherapy, and chemotherapy; however, GBM is heterogeneous and present therapies are ineffective. Tumor treating fie…
Abstract Functionalized superparamagnetic iron oxide nanoparticles (SPIONs) have emerged as potential clinical tools for cancer theranostics. Membrane-bound 70 kDa heat shock protein (mHsp70) is ubiquitously expressed on the cell membrane of various tumor types but not on normal cells and therefore provides a tumor-sp…
Abstract Glioblastomamultiforme (GBM) is a dreadful primary brain tumor characterized with extremely poor prognosis and survival rate, despite available treatments. The failure of current therapies to eliminate specific subpopulations within heterogeneous GBM has been considered a key factor contributing to the inevit…
Abstract Traditional treatment methods for glioblastoma multiforme (GBM) including resection, radiation, and chemotherapy have been largely unsuccessful, with a current 5-year survival rate of 5.6%. In this project we examine the potential of nanosized self-assembling peptide hydrogels to locally deliver and convert t…
Abstract Introduction: A novel proprietary nano-combination therapy (Hybrid-Nanoengineering) combination of paclitaxel and bioavailable curcumin (nano-paclitaxel-curcumin or NPC) has been created and shown to be stable as a dry powder and was effective in treating pancreatic cancer in preclinical models. Experimental…
Abstract The Rho GTPases Rac and Cdc42 are potential targets against metastatic disease. Our group characterized the small molecule MBQ-167 as an effective dual Rac/Cdc42 inhibitor that reduces HER2 positive and triple negative tumor growth and metastasis in mice by ~90%. To continue validating this drug for FDA appro…
Abstract The prognosis of pancreatic ductal adenocarcinoma (PDAC) patients remains poor, and new effective therapies are urgently needed. Cytotoxic gemcitabine (GEM) is currently used as a standard-of-care drug for PDAC treatment but its efficacy is greatly compromised mainly due to quick metabolism in the body and dr…
Abstract Celastrol (CL), a compound isolated from Tripterygium wilfordii, possesses various bioactivities such as anti-tumor, anti-inflammatory and anti-obesity effects. Many new drug delivery systems of CL have been designed to overcome its poor water solubility and low bioavailability. However, few studies are avail…
Abstract Objectives: Personalized therapies target individual, tumor-specific alterations identified by descriptive genomics and transcriptomics. Selecting individual targets with high therapeutic potential remains a challenging task for Molecular Tumor Boards in today's clinical routine. Functional data, which help r…
Abstract In the United States, non-small cell lung cancer (NSCLC) is the largest contributor to cancer mortality. Traditional chemotherapies are toxic, and drug-resistance development is common. Recently, several drug candidates were shown to selectively induce lysosomal membrane permeabilization in aggressive tumors.…
Abstract Multiple Myeloma (MM) is a recurring-relapsing plasma cell malignancy, which invariably develops drug resistance. Acquired resistance often involves mutation of drug targets or activation of compensatory pathways, making new targets in high demand. Physical contact of MM cells (MMC) with the bone microenviron…
Abstract Triapine, which is currently tested in a clinical phase III trial, is the best-studied thiosemicarbazone (TSC) for anticancer therapy. With regard to the mode of action, anticancer activity of TSCs is frequently linked to their ability to chelate essential metal ions such as copper and iron. As Triapine monot…
Abstract Despite Pancreatic cancer being expected to contribute to only 3% of new cancer cases in both males and females in 2019, it is expected to cause an estimated 45,750 deaths making it the third highest contributor to cancer deaths. This is due to the low survivability associated with pancreatic cancer which has…